Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01SJS
|
|||
| Former ID |
DIB016805
|
|||
| Drug Name |
AXL-1717
|
|||
| Synonyms |
BVT-51004; IGF-1 inhibitors, Axelar/Biovitrum; IGF-1 inhibitors, Karolinska/Biovitrum; Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1], [2] | |
| Company |
Axelar AB
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22O8
|
|||
| Canonical SMILES |
COC1=CC(=CC(=C1OC)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)O
|
|||
| InChI |
1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19+,20-/m0/s1
|
|||
| InChIKey |
YJGVMLPVUAXIQN-HAEOHBJNSA-N
|
|||
| CAS Number |
CAS 477-47-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
93086, 602433, 8138202, 8195191, 11364530, 11367092, 11369654, 11372800, 11375671, 11377816, 11484215, 11488336, 11491486, 11493650, 11495450, 11537779, 14831259, 14929033, 26612705, 26680654, 26758962, 29216394, 43128600, 47423461, 48317613, 48410508, 49971903, 50110901, 53787335, 57318718, 71831592, 78208362, 85787406, 91010625, 92124958, 92718093, 103192207, 104352939, 124637742, 126628593, 135148884, 142572795, 152104948, 162198638, 162248061, 163620930, 163686251, 163687885, 163835502, 174006597
|
|||
| ChEBI ID |
CHEBI:75251
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7873). | |||
| REF 2 | ClinicalTrials.gov (NCT01561456) Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung. U.S. National Institutes of Health. | |||
| REF 3 | Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.